From L-R: Scarlet scientific founders Ash Toye and Jan Frayne, and CEO Alistair Irvine
In wake of Rubius downfall, a new biotech spinout launches to 'take the next step' in red blood cell therapies
When Alistair Irvine first started raising money for a University of Bristol spinout named Scarlet Therapeutics about two years ago, he got one question a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
